Summary
This BMJ article argues that while pharmaceutical company campaigns to destigmatise obesity may promote accurate and important messages about compassion and the biological complexity of obesity, they also deserve critical scrutiny because the companies behind them have a commercial interest in expanding the market for obesity treatments.
Using Eli Lilly’s UK “Obesity is a Disease” campaign as an example, the authors contend that such campaigns can subtly encourage people to seek clinical solutions, particularly weight-loss drugs such as tirzepatide, while drawing attention away from the broader social, environmental and economic causes of obesity, including deprivation, food environments and urban planning.
Recommended Comments
Create an account or sign in to comment